Ticagrelor Outperforms Clopidogrel for Unstable Angina with Better Inflammation Reduction

Ticagrelor reduced angina frequency, duration, and inflammatory markers more effectively than clopidogrel in patients with unstable angina.

Qin, Donghui et al.·Pakistan journal of pharmaceutical sciences·2025·low-moderaterct
RPEP-13144Rctlow-moderate2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
rct
Evidence
low-moderate
Sample
N=Not specified in abstract
Participants
Patients with coronary heart disease and unstable angina

What This Study Found

Ticagrelor was superior to clopidogrel for angina symptoms and inflammatory marker reduction in unstable angina patients.

Key Numbers

Ticagrelor vs clopidogrel; lower BNP, CRP, IL-6, IL-18, MMP-9, TNF-alpha, and multiple other markers in the ticagrelor group (all P<0.05).

How They Did This

Comparative clinical study measuring angina symptoms and a comprehensive inflammatory biomarker panel.

Why This Research Matters

Choosing the right antiplatelet drug affects not just clotting but also the inflammatory processes driving coronary disease.

The Bigger Picture

Ticagrelor's anti-inflammatory properties may contribute to its cardiovascular benefits beyond platelet inhibition alone.

What This Study Doesn't Tell Us

Single study — specific methodology not detailed in abstract. Inflammatory markers are secondary to clinical outcomes.

Questions This Raises

  • ?Are ticagrelor's anti-inflammatory effects direct or secondary to better platelet inhibition?
  • ?Do these inflammatory benefits translate to fewer heart attacks long-term?

Trust & Context

Key Stat:
Multiple markers Ticagrelor reduced CRP, IL-6, IL-18, MMP-9, MPO, ET-1, TNF-α more than clopidogrel
Evidence Grade:
Clinical comparative study — supportive evidence consistent with larger trial results favoring ticagrelor.
Study Age:
Published in 2025, adding inflammatory biomarker data to the ticagrelor vs. clopidogrel comparison.
Original Title:
Efficacy of ticagrelor and clopidogrel in treating unstable angina and their effects on serum inflammatory factors.
Published In:
Pakistan journal of pharmaceutical sciences, 38(1), 77-82 (2025)
Database ID:
RPEP-13144

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Is ticagrelor better than clopidogrel?

For unstable angina, this study found ticagrelor reduced symptoms and inflammation more effectively, consistent with major trial evidence.

Why do anti-clotting drugs reduce inflammation?

Ticagrelor may have direct anti-inflammatory effects beyond platelet inhibition, reducing inflammatory molecules that drive heart disease.

Read More on RethinkPeptides

Cite This Study

RPEP-13144·https://rethinkpeptides.com/research/RPEP-13144

APA

Qin, Donghui; Ren, Yuanyuan; Zhang, Na; Yang, Xue; Chen, Zhuo; Zhao, Changliang. (2025). Efficacy of ticagrelor and clopidogrel in treating unstable angina and their effects on serum inflammatory factors.. Pakistan journal of pharmaceutical sciences, 38(1), 77-82.

MLA

Qin, Donghui, et al. "Efficacy of ticagrelor and clopidogrel in treating unstable angina and their effects on serum inflammatory factors.." Pakistan journal of pharmaceutical sciences, 2025.

RethinkPeptides

RethinkPeptides Research Database. "Efficacy of ticagrelor and clopidogrel in treating unstable ..." RPEP-13144. Retrieved from https://rethinkpeptides.com/research/qin-2025-efficacy-of-ticagrelor-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.